白细胞介素-2联合化疗对急性髓系白血病T淋巴细胞亚群影响的研究

目的 探讨急性髓系白血病患者化疗后应用白细胞介素-2(IL2)治疗对细胞免疫功能的影响及其临床意义.方法 将54例急性髓系白血病患者按随机数字表法分为IL-2联合化疗组(治疗组,28例)和单纯化疗组(对照组,26例),治疗组于化疗后每天加用IL-2 40万U静脉滴注,连用2周,检测两组治疗前后T淋巴细胞亚群的变化.结果 治疗组治疗后CD3(0.6026±0.2275)、CD4(0.4972±0.1224)、CD56(0.3016±0.1053)明显高于治疗前(分别为0.3926±0.2010、0.2264±0.1190、0.1729±0.1226)及对照组治疗后(分别为0.4352±0.1930、0.2738±0.1362、0.1937±0.1268),差异均有统计学意义(P<0.05).结论 IL-2联合化疗能明显提高急性髓系白血病患者T淋巴细胞亚群的水平,对提高机体的免疫功能有积极的作用.

Abstract：

Objective To investigate the influence and the clinical significance of interleukin-2 (IL-2) on T lymphocyte subgroup after chemotherapy in acute myeloid leukemia patients. Methods Fiftyfour acute myeloid leukemia patients were divided into treatment group (chemotherapy combined with IL-2,28 cases) and control group (pure chemotherapy,26 cases) by radom digits table. In treatment group, IL-2400 000 U was dripped after chemotherapy for 14 days. Then the T lymphocyte subgroup change before and after treatment was examined. Results After 14 days' treatment, the levels of CD3 (0.6026±0.2275 ),CD4(0.4972±0.1224),CD56(0.3016±0.1053 ) in treatment group were significantly higher than those before treatment(0.3926±0.2010,0.2264±0.1190,0.1729±0.1226) and in control group (0.4352±0.1930,0.2738±0.1362,0.1937±0.1268)(P< 0.05). Conclusion IL-2 treatment can obviously raise the levels of T lymphocyte subgroup and can raise the immunologic function.

The influence of combined treatment of interleukin-2 and chemotherapy on T lymphocyte subgroup in acute myeloid leukemia

Objective To investigate the influence and the clinical significance of interleukin-2 (IL-2) on T lymphocyte subgroup after chemotherapy in acute myeloid leukemia patients. Methods Fiftyfour acute myeloid leukemia patients were divided into treatment group (chemotherapy combined with IL-2,28 cases) and control group (pure chemotherapy,26 cases) by radom digits table. In treatment group, IL-2400 000 U was dripped after chemotherapy for 14 days. Then the T lymphocyte subgroup change before and after treatment was examined. Results After 14 days' treatment, the levels of CD3 (0.6026±0.2275 ),CD4(0.4972±0.1224),CD56(0.3016±0.1053 ) in treatment group were significantly higher than those before treatment(0.3926±0.2010,0.2264±0.1190,0.1729±0.1226) and in control group (0.4352±0.1930,0.2738±0.1362,0.1937±0.1268)(P< 0.05). Conclusion IL-2 treatment can obviously raise the levels of T lymphocyte subgroup and can raise the immunologic function.